Development · 19 Sep 2026
DRREDDY, full dossier7 publishers have reported this development. Each act of reporting is below, cited.
Takeda's QDENGA is expected to become available in India in the first half of 2027, following an exclusive partnership with Dr Reddy’s Laboratories for its promotion and distribution in the private market.
Dr Reddy's shares gained up to 2% on Friday, September 18, after the company announced a partnership with Japanese drugmaker Takeda Pharmaceutical to promote and distribute its Qdenga dengue vaccine in India.
Dr Reddy’s Laboratories has obtained exclusive rights to promote and distribute Takeda’s dengue vaccine, Qdenga, across India’s private market, with the vaccine anticipated to become available in the first half of 2027.
Dr Reddy’s Laboratories has entered into an exclusive agreement with Japan-based Takeda Pharmaceutical to promote and distribute its dengue vaccine QDENGA in India’s private market.
Dr Reddy's Laboratories will distribute Takeda's Qdenga dengue vaccine in India, with availability expected in the first half of 2027.
Dr Reddy's Laboratories will distribute Takeda's QDENGA dengue vaccine in India's private market, with initial doses imported from Germany.
Dr Reddy's Laboratories signed an agreement with Takeda Pharmaceutical to promote and distribute the Qdenga dengue vaccine in India.
29 Sep 2026 · 1 publisher
Dr Reddys Laboratories Ltd is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE.
24 Sep 2026 · 2 publishers
Dr Reddys Laboratories Ltd gained for a fifth straight session on September 23, 2026.
23 Sep 2026 · 1 publisher
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.